RT Journal Article
SR Electronic
T1 Systemic lymphoblastoid interferon therapy in chronic progressive multiple Sclerosis. I. Clinical and MRI evaluation
JF Neurology
JO Neurology
FD Lippincott Williams & Wilkins
SP 479
OP 479
DO 10.1212/WNL.40.3_Part_1.479
VO 40
IS 3 Part 1
A1 Kastrukoff, L. F.
A1 Oger, J. J.
A1 Hashimoto, S. A.
A1 Sacks, S. L.
A1 Li, D. K.
A1 Palmer, M. R.
A1 Koopmans, R. A.
A1 Petkau, A. J.
A1 Berkowitz, J.
A1 Paty, D. W.
YR 1990
UL http://n.neurology.org/content/40/3_Part_1/479.abstract
AB A randomized, double-blind, placebo-controlled, noncrossover trial determined the efficacy of lymphoblastoid interferon (IFN) in chronic progressive multiple sclerosis (CP MS). Fifty patients received 5 × lo6 IUIFN subcutaneously daily for 6 months while 50 received placebo. After 2 years, there were no significant differences between the 2 groups based on clinical evaluations and quantitative MRI analysis of the brain, although a trend was observed in the IFN group. Clinically, the IFN group was worse at 1 and 3 months and improved at 6 to 18 months, when compared with the placebo group. Results of MRI evaluations of the brain at 6 months support this trend. This trend likely resulted from a subpopulation of 10 IFN-treated patients, characterized by a higher women: men ratio and a lower EDSS score at entry into the trial. We cannot recommend lymphoblastoid IFN as treatment for CP MS at this time.